-- (Updates with Inhibrx response to a request for comment from.)
Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported Wednesday, citing people familiar with the matter.
Inhibrx is exploring a joint spin-off of the treatment, INBRX-106, as well as a second experimental cancer drug, which could have a combined value of more than $9 billion if clinical trials succeed, the people told Reuters.
Inhibrx declined to comment to, while Merck and Ono Pharmaceutical didn't immediately reply to requests for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: $112.88, Change: $+0.32, Percent Change: +0.28%